Roche Sees China Drag Peaking In 2025 As Diagnostics Bets On Innovation Pipeline

Newly Cleared Alzheimer’s And Kidney Disease Assays Help Offset Headwinds From China’s Pricing Reforms.

 
• By Shubham Singh
Diagnostics sales grew 1% during the third quarter of 2025, a performance Sause attributed to pricing reforms and policy changes in China that “severely impacted” the business this year. Picture Courtesy: Shutterstock

More from Strategy

More from Business